US Patent 9,284,314: Avibactam Process Claims, Scope, Expiration and Generic Risk

US Patent 9,284,314 protects manufacturing processes for avibactam, including conversion of a protected hydroxylamine piperidine intermediate into the diazabicyclooctane core and subsequent sulfation. Its strongest commercial relevance is to sodium avibactam, the beta-lactamase inhibitor in AVYCAZ and Zavicefta. The patent is primarily a process patent, not a broad composition-of-matter patent. Claims 10 through 15 narrow the estate to avibactam-specific intermediates, reagents and product-by-process language.

The patent can create manufacturing and ANDA litigation risk where a proposed generic uses the claimed intermediate sequence, particularly the conversion of the Formula (III) carboxamide into the bicyclic carbamate and the subsequent SO3-complex sulfation step. It does not, based on the supplied claims, prevent every process for making avibactam.

What drug does US Patent 9,284,314 protect?

The patent covers processes for preparing sodium avibactam and closely related diazabicyclooctane compounds.

Item	Description
Patent	US 9,284,314 B2
Grant date	March 15, 2016
Active ingredient	Avibactam
Commercial form	Sodium avibactam
Brand products	AVYCAZ in the United States; Zavicefta in Europe and other markets
Drug class	Non-beta-lactam beta-lactamase inhibitor
Combination partner	Ceftazidime in AVYCAZ
Claim type	Chemical manufacturing process and product-by-process
Principal commercial issue	Whether a generic manufacturer uses the claimed avibactam route or an equivalent process

The claimed target in claims 10, 11 and 15 is the trans-diazabicyclooctane sulfonate corresponding to avibactam. Claim 11 identifies the sodium salt:

“sodium ({[(2S,5R)-2-carbamoyl-7-oxo-1,6-diazabicyclo[3.2.1]oct-6-yl]oxy}sulphonyl)oxidanide.”

That structure is sodium avibactam.

What are the main limitations of claim 1?

Claim 1 requires a two-stage process.

First, a compound of Formula (II) is treated with a nitrogen source or amine to form Formula (III). Second, Formula (III) is treated with a protecting group and a carbonylation agent to form Formula (I), subject to the broad R-group definitions.

The functional sequence is:

Start with a protected or substituted piperidine-related intermediate.
Introduce or convert the nitrogen functionality.
Form the carboxamide or related carbonyl derivative.
Cyclize to the 1,6-diazabicyclo[3.2.1]octane framework.
Protect or activate the relevant nitrogen or hydroxylamine functionality.
Sulfate the bicyclic intermediate when the optional SO3-complex step is used.

The broad Formula (I), Formula (II) and Formula (III) definitions create substantial chemical breadth on paper. The practical scope is narrower because a process must satisfy the claimed sequence and the required structural relationships among R1 through R7.

What does claim 1 require for infringement?

A potentially infringing process would generally need to include:

A Formula (II) starting material;
Treatment with a nitrogen source or amine;
Formation of a Formula (III) intermediate;
Treatment of Formula (III) with a protecting group;
Treatment with a carbonylation agent;
A product falling within Formula (I) or an identified pharmaceutically acceptable derivative.

The claim uses “comprising,” which ordinarily allows additional process steps. A manufacturer cannot avoid the claim merely by adding purification, isolation, solvent exchange, crystallization or salt-formation steps.

The process may be vulnerable to design-around strategies if a competitor:

Uses a different starting material;
Introduces the carboxamide before the claimed nitrogen-conversion step;
Forms the bicyclic core through a different cyclization sequence;
Uses a route that does not treat Formula (III) with the claimed combination of protecting group and carbonylation agent;
Uses a different order of sulfation and cyclization;
Produces avibactam through a non-equivalent reaction sequence.

How do claims 2 through 9 narrow the patent?

Claims 2 through 9 define alternative embodiments within claim 1.

Claim	Limitation	Commercial significance
2	R1, R2 and R7 are hydrogen; R3 is OSO3H	Narrows to a sulfated bicyclic structure
3	R1 is piperidinyl; R2 and R7 are hydrogen; R3 is OSO3H	Covers a particular substituted precursor or analog
4	R4 is benzyloxy	Protecting-group embodiment
5	R5 is benzyloxy; R6 and R7 are hydrogen	Relevant to protected hydroxylamine chemistry
6	R5 is allyl or trialkylsilyl; R6 is hydrogen	Alternative protecting-group embodiments
7	Uses 9-fluorenylmethoxycarbonyl	Identifies an Fmoc-type protection step
8	Uses N,N-carbonyldiimidazole	Identifies CDI as the carbonylation agent
9	Uses an SO3 complex	Relevant to sulfation of the bicyclic intermediate

Claims 7 and 8 are especially useful for infringement analysis because they identify specific reagents rather than relying only on broad functional language. A process using Fmoc chemistry and CDI may fall within these dependent claims if the other claim 1 limitations are met.

Claim 9 addresses sulfation using an SO3 complex. This is commercially important because avibactam’s sulfate functionality is central to the final active ingredient. A manufacturer using sulfur trioxide-pyridine, sulfur trioxide-trimethylamine or another qualifying SO3 complex may face a claim construction dispute over the meaning of “SO3 complex” and the structural form of the resulting product.

What do claims 10 through 15 cover for avibactam?

Claims 10 through 15 provide the most direct connection to commercial sodium avibactam.

Claims 10 and 11: avibactam-specific processes

Claim 10 covers a process in which Formula (I) is trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide or a pharmaceutically acceptable salt.

Claim 11 narrows the product to sodium avibactam. These claims are narrower than claim 1 but more valuable in a commercial dispute because they identify the actual drug substance.

Claims 12 and 13: identified starting and intermediate compounds

Claim 12 specifies benzyl (2S,5R)-5-[(benzyloxy)amino]piperidine-2-carboxylate ethanedioate as the Formula (II) compound.

Claim 13 specifies (2S,5R)-5-[(benzyloxy)amino]piperidine-2-carboxamide as Formula (III).

These claims create an identifiable route marker. If a generic manufacturer purchases or generates this specific intermediate, the patent holder may have a direct basis for process infringement allegations, subject to proof of the complete claimed process.

Claim 14: bicyclic intermediate formation

Claim 14 covers conversion of the Formula (III) carboxamide into (2S,5R)-6-(benzyloxy)-7-oxo-1,6-diazabicyclo[3.2.1]octane-2-carboxamide.

This is likely one of the most commercially relevant process steps because it forms the constrained bicyclic core before deprotection and sulfation.

Claim 15: product-by-process claim

Claim 15 covers avibactam-related material “prepared according to the process of claim 1.”

Under US patent law, product-by-process claims generally require the claimed product to have the recited product characteristics, while the process language can create a dispute over whether the product is distinguishable by structure or properties. The Federal Circuit has treated product-by-process claims as product claims for infringement, although the process limitations remain relevant to claim construction and validity analysis.[4]

Claim 15 therefore should not be treated as a simple standalone composition claim. Its practical value depends on:

Whether the product is structurally or chemically distinguishable from avibactam made by another process;
How the court construes “prepared according to the process of claim 1”;
Whether the accused product has the same claimed characteristics;
Whether the claim is invalid for lack of clarity, written description or enablement across its breadth.

How strong is the patent estate for avibactam?

US 9,284,314 is strongest against a manufacturer using the specific protected hydroxylamine piperidine route described in claims 12 through 14. It is weaker against a fully independent synthetic route.

Strength factor	Assessment
Coverage of sodium avibactam	Strong in claims 10, 11 and 15, subject to process limitations
Coverage of the exact disclosed route	Strong
Coverage of all avibactam manufacturing routes	Limited
Coverage of Fmoc chemistry	Specific and potentially useful under claim 7
Coverage of CDI carbonylation	Specific and potentially useful under claim 8
Coverage of sulfation	Relevant under claim 9
Composition-of-matter protection	Not established by the supplied claims
Intermediate protection	Meaningful under claims 12 through 14
Design-around exposure	Moderate to high
Process-detection difficulty	High if the process occurs outside the United States
ANDA litigation value	Potentially material if the route is disclosed or discoverable

The patent’s commercial strength depends less on the broad R-group language than on the route-specific dependent claims. Generic manufacturers commonly seek to avoid disclosing commercially sensitive process details in a way that directly maps onto narrow process claims. Patent holders can seek discovery of batch records, reaction specifications, supplier information and regulatory submissions, but proving infringement of a manufacturing process can be more difficult than proving infringement of a composition claim.

When does US Patent 9,284,314 lose exclusivity?

The patent’s ordinary term is generally measured from the applicable US nonprovisional filing date, not from the March 15, 2016 grant date.[1] Public patent records associate the patent family with an approximately 2031 expiration horizon, subject to patent-term adjustment, terminal disclaimers and any other term events recorded by the USPTO.

Exclusivity category	Relevance to avibactam
Patent term under US law	Approximately through 2031 for this patent family, subject to USPTO term calculation
FDA new chemical entity exclusivity	AVYCAZ received five-year NCE exclusivity beginning with approval
QIDP exclusivity	AVYCAZ qualified for an additional five years under the Generating Antibiotic Incentives Now framework
Regulatory exclusivity end	Regulatory exclusivity does not necessarily match the process-patent term
Patent-term extension	The supplied claims do not establish that this patent received PTE
Orange Book status	Process-patent listing must be confirmed against the current FDA publication

AVYCAZ was approved by the FDA on February 5, 2015, for specified serious bacterial infections.[2] The product received qualified infectious disease product treatment, which extended applicable exclusivity under the Food, Drug, and Cosmetic Act.[3] That regulatory exclusivity period is separate from US 9,284,314 and does not convert the process patent into a composition patent.

What is the Orange Book status of US 9,284,314?

A process patent does not automatically appear in the Orange Book. FDA listing turns on whether the patent claims the drug substance, drug product, formulation or an approved method of use, and whether the NDA holder properly submits the patent for listing.[5]

Based on the supplied claims, US 9,284,314 is primarily directed to manufacturing processes. Claims 10 and 11 identify avibactam, but they remain embedded in claim 1’s process framework. Claim 15 is product-by-process language. The patent therefore has a materially different listing profile from:

An avibactam composition patent;
A ceftazidime-avibactam formulation patent;
A patent claiming the AVYCAZ dosage regimen;
A patent claiming an approved indication.

The patent’s presence or absence in the current Orange Book must be determined from the FDA’s patent-and-exclusivity listing for the relevant NDA. An Orange Book listing would increase the probability of a Paragraph IV notice and patent litigation, but absence from the Orange Book would not eliminate infringement risk for commercial manufacture under 35 U.S.C. § 271(g) or other applicable provisions.[1,5]

What Paragraph IV challenges and generic entry risks exist?

A generic applicant seeking approval for a ceftazidime-avibactam product could pursue several certification strategies:

Paragraph III certification if a listed patent remains valid and enforceable;
Paragraph IV certification if the applicant alleges invalidity, unenforceability or noninfringement;
A section viii statement for a patent limited to an unapproved method of use;
A certification strategy based on a noninfringing manufacturing route where the patent is process-focused.

For this patent, a Paragraph IV case would likely center on the following issues:

Whether the ANDA applicant’s avibactam manufacturing process practices every limitation of claim 1.
Whether the applicant uses the specified Formula (II) and Formula (III) intermediates.
Whether the claimed protecting-group and carbonylation sequence is present.
Whether the accused sulfation step uses an SO3 complex within claim 9.
Whether claims 10, 11 and 15 are invalid or improperly broadened beyond the enabling disclosure.
Whether the claims satisfy written-description and enablement requirements across the extensive Markush definitions.
Whether the manufacturing occurs in the United States or produces a product imported into the United States.

The principal generic-entry scenario is therefore route substitution rather than simple invalidation. A generic applicant may attempt to obtain approval while using a noninfringing process, but the feasibility of that strategy depends on process yield, stereochemical control, impurity profile, scale-up performance and regulatory comparability.

Which companies are competing with avibactam?

Avibactam competes in the hospital market with other beta-lactamase inhibitor combinations and newer antibiotics.

Product	Active components	Company	Key competitive point
AVYCAZ	Ceftazidime-avibactam	Pfizer, following predecessor commercialization arrangements	Broad activity against many class A and class C beta-lactamases
Vabomere	Meropenem-vaborbactam	Melinta Therapeutics	Strong positioning against KPC-producing Enterobacterales
Recarbrio	Imipenem-cilastatin-relebactam	Merck	Carbapenem-based combination with beta-lactamase inhibition
Fetroja	Cefiderocol	Shionogi	Siderophore cephalosporin; not a beta-lactamase inhibitor combination
Zerbaxa	Ceftolozane-tazobactam	Merck	Competes in serious Gram-negative infections

Avibactam has a distinct mechanism and spectrum. It inhibits class A, class C and some class D beta-lactamases, while activity varies by enzyme and bacterial species.[2] Competitive substitution is driven by local resistance patterns, formulary policy, renal dosing, susceptibility data and hospital antimicrobial stewardship.

What manufacturing and IP barriers affect generic avibactam?

The key technical barriers are stereochemical integrity, bicyclic-core formation, sulfate installation and control of residual protecting-group impurities.

Stereochemistry

The claims identify the (2S,5R) configuration. A process that generates or resolves the wrong stereoisomer may fail commercially even if it avoids infringement. Stereochemical control is therefore both a quality requirement and a process-development barrier.

Bicyclic-core construction

The 1,6-diazabicyclo[3.2.1]octane ring system is the central structural element. The claimed conversion of the protected amino piperidine carboxamide into the bicyclic intermediate may offer process advantages in yield or selectivity. A competing route must match the required impurity profile at commercial scale.

Sulfation and salt formation

The sulfate group is chemically sensitive. Sulfation conditions can affect degradation, regioselectivity, residual reagents and purification. Final sodium-salt isolation also affects polymorphic or solid-state properties, although the supplied claims do not establish a separate solid-form claim.

Geographic manufacturing exposure

A process performed entirely outside the United States may still create US exposure if the resulting product is imported into the United States. Section 271(g) addresses importation into the United States of a product made by a patented process, subject to statutory exceptions.[1] This is important for contract manufacturers and suppliers of avibactam API.

What litigation and settlement issues should be monitored?

The principal litigation triggers are:

An ANDA filing for ceftazidime-avibactam;
A Paragraph IV notice identifying US 9,284,314;
Discovery of Formula (II) or Formula (III) intermediates in the generic route;
Importation of avibactam API made overseas;
A licensing agreement covering avibactam API or the claimed process;
A settlement providing a negotiated generic launch date.

A settlement may include a delayed-entry provision, supply arrangement, process license, covenant not to sue or confidential manufacturing restrictions. The patent number alone does not establish that a settlement exists. Any commercial assessment should distinguish this patent from separate AVYCAZ composition, formulation and method-of-use patents.

How does US 9,284,314 compare with composition and formulation patents?

Patent category	What it protects	Risk to generic
Composition patent	Avibactam molecule or salt	Highest if valid and unexpired
Combination-product patent	Ceftazidime-avibactam product	High for the specific combination
Formulation patent	Physical dosage form or stability system	Moderate to high depending on ANDA formulation
Method-of-use patent	Approved treatment method	Relevant to labeling and section viii strategy
Process patent	Manufacturing route	Route-dependent
Intermediate patent	Key protected precursor or bicyclic intermediate	Material where the generic uses the same intermediate
Product-by-process patent	Product associated with a specified process	Fact-intensive and vulnerable to construction disputes

US 9,284,314 is most valuable as a process and intermediate patent. It should not be valued as the sole barrier to generic entry unless the patent holder can show that commercially practical alternative routes are unavailable or uneconomic.

Key Takeaways

US 9,284,314 is directed principally to processes for preparing avibactam and sodium avibactam.
Claim 1 requires a specific Formula (II) to Formula (III) conversion followed by protecting-group and carbonylation treatment.
Claims 10, 11 and 15 tie the patent directly to avibactam, but they retain process or product-by-process limitations.
Claims 12 through 14 are important route-specific claims covering identified avibactam intermediates and bicyclic-core formation.
Claims 7 through 9 identify Fmoc, CDI and SO3-complex embodiments.
The patent does not, based on the supplied claims, cover every possible method of manufacturing avibactam.
The patent has an approximately 2031 ordinary-term horizon based on the public patent family, subject to the USPTO’s final term calculation.
AVYCAZ’s FDA regulatory exclusivity and this patent’s term are separate rights.
Generic risk is highest where an ANDA applicant uses the protected hydroxylamine piperidine route or imports API made by that route.
Biosimilar risk is not applicable because avibactam and AVYCAZ are small-molecule products regulated through the NDA/ANDA framework.

FAQs

Can a generic manufacturer avoid US 9,284,314 by using a different avibactam salt?

Not necessarily. Changing the final salt may avoid a narrow salt limitation, but it will not avoid process claims that are infringed before salt formation. The complete manufacturing sequence must be analyzed.

Does claim 11 cover sodium avibactam made by any process?

Claim 11 is written as a dependent process claim. It requires the process limitations inherited from claim 1. It is not equivalent to an unrestricted composition-of-matter claim for sodium avibactam.

Is a process performed in India or China outside the scope of the patent?

Not automatically. Importing into the United States a product made by a patented process can create liability under 35 U.S.C. § 271(g), subject to statutory exceptions.

Does a product-by-process claim automatically expire when the process changes?

No. The legal effect depends on claim construction, product identity, process limitations and the infringement and validity standards applied by the court.

Are biosimilars relevant to AVYCAZ patent risk?

No. AVYCAZ is a small-molecule drug combination. The relevant competitors are ANDA applicants and other antibiotic products, not biosimilar applicants under the Public Health Service Act.

References

United States Patent and Trademark Office. (2024). Manual of Patent Examining Procedure: Patent term and patent infringement provisions. U.S. Department of Commerce.
U.S. Food and Drug Administration. (2015). FDA approves new antibacterial drug Avycaz. https://www.fda.gov
U.S. Congress. (2012). Food and Drug Administration Safety and Innovation Act, Pub. L. No. 112-144, § 801, 126 Stat. 993.
United States Court of Appeals for the Federal Circuit. (2008). Abtox, Inc. v. Exitron Corp., 131 F.3d 1009; Abbott Laboratories v. Sandoz, Inc., 566 F.3d 1282.
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.fda.gov
U.S. Patent No. 9,284,314 B2. (2016). Process for preparing diazabicyclooctane compounds. United States Patent and Trademark Office.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Abbvie	AVYCAZ	avibactam sodium; ceftazidime	POWDER;INTRAVENOUS	206494-001	Feb 25, 2015		RX	Yes	Yes	⤷ Start Trial	⤷ Start Trial		Y			⤷ Start Trial
Abbvie	EMBLAVEO	avibactam sodium; aztreonam	POWDER;INTRAVENOUS	217906-001	Feb 7, 2025		RX	Yes	Yes	⤷ Start Trial	⤷ Start Trial		Y			⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	086972	⤷ Start Trial
Australia	2012270051	⤷ Start Trial
Brazil	112013032415	⤷ Start Trial
Canada	2780403	⤷ Start Trial
China	103649051	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 9,284,314

Which drugs does patent 9,284,314 protect, and when does it expire?

Summary for Patent: 9,284,314